{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:56:06Z","timestamp":1788857766752,"version":"build-2803163510"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:p>Tenosynovial giant cell tumors (TGCTs) are a spectrum of benign growths that can occur in both intra-articular and extra-articular locations. The pattern of involvement also varies from nodular, typically small-volume disease to extensive and diffuse synovial infiltration. Surgical resection remains the treatment of choice for most patients and resection techniques include arthroscopic, open, or a combined approach. However, TGCT can be locally aggressive and exhibit high recurrence rates even after adequate surgical removal. Improved understanding of the complex genetic and environmental factors that lead to these proliferative disorders have modernized treatment options. Discovery of the unique role that tumor cell expression of the colony-stimulating-factor1 and propagation of the inflammatory cascade has led to the use of adjuvant medications to improve outcomes. In-depth knowledge of the etiology, clinical presentation, diagnosis, workup, historical treatments, and new treatment options for patients with TGCT are crucial for orthopaedic surgeons to understand and work effectively with a multidisciplinary treatment team.<\/jats:p>","DOI":"10.5435\/jaaos-d-24-01255","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:19:18Z","timestamp":1742951958000},"page":"e593-e602","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis"],"prefix":"10.5435","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0670-5103","authenticated-orcid":false,"given":"Alysia K.","family":"Kemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Brigman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Popkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakenda K.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"R3-20250813","first-page":"185","article-title":"Cancer de la gaine des tendons","volume":"47","author":"Chassaignac","year":"1852","journal-title":"Gaz Hop Civ Milit"},{"key":"R4-20250813","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2106\/00004623-198769060-00026","article-title":"Pigmented villonodular synovitis","volume":"69","author":"Flandry","year":"1987","journal-title":"J Bone Joint Surg Am"},{"key":"R5-20250813","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00003086-199401000-00028","article-title":"Diagnostic features of diffuse pigmented villonodular synovitis of the knee","volume":"298","author":"Flandry","year":"1994","journal-title":"Clin Orthop Relat Res"},{"key":"R6-20250813","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2106\/00004623-196749010-00010","article-title":"Localized pigmented villonodular synovitis of the knee: Report of five cases","volume":"49","author":"Granowitz","year":"1967","journal-title":"J Bone Joint Surg Am"},{"key":"R7-20250813","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-018-5188-6","article-title":"Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: Initial experience of molecularly targeted therapy","volume":"18","author":"Nakayama","year":"2018","journal-title":"BMC Cancer"},{"key":"R8-20250813","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/PAS.0b013e318158428f","article-title":"Malignant diffuse-type tenosynovial giant cell tumors: A series of 7 cases comparing with 24 benign lesions with review of the literature","volume":"32","author":"Li","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R9-20250813","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","article-title":"Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis","volume":"23","author":"Ravi","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"R10-20250813","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides","volume":"31","author":"Cupp","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R11-20250813","first-page":"e20.00028","article-title":"Management of tenosynovial giant cell tumor: A neoplastic and inflammatory disease","volume":"4","author":"Healey","year":"2020","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"R12-20250813","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20250813","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-22-1898","article-title":"Interactions in CSF1-driven tenosynovial giant cell tumors","volume":"28","author":"van Ijzendoorn","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R14-20250813","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"key":"R15-20250813","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00005792-198005000-00004","article-title":"Pigmented villonodular synovitis and tenosynovitis: A clinical epidemiologic study of 166 cases and literature review","volume":"59","author":"Myers","year":"1980","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250813","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12969-018-0222-4","article-title":"Pigmented villonodular synovitis in pediatric population: Review of literature and a case report","volume":"16","author":"Karami","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"R17-20250813","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13023-021-01883-5","article-title":"Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: An observational disease registry","volume":"16","author":"Lopez-Bastida","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R18-20250813","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","article-title":"Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)","volume":"103","author":"Gouin","year":"2017","journal-title":"Orthop Traumatol Surg Res"},{"key":"R19-20250813","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/RLU.0000000000000893","article-title":"Pigmented villonodular synovitis: Potential pitfall on oncologic 18F-FDG PET\/CT","volume":"41","author":"Broski","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R20-20250813","first-page":"e21.00217","article-title":"Arthroscopic versus open management of diffuse-type tenosynovial giant cell tumor of the knee: A meta-analysis of retrospective cohort studies","volume":"4","author":"Chandra","year":"2021","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"R21-20250813","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.arthro.2014.04.101","article-title":"Treatment of pigmented villonodular synovitis of the knee","volume":"30","author":"Aur\u00e9gan","year":"2014","journal-title":"Arthroscopy"},{"key":"R22-20250813","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/CORR.0000000000002934","article-title":"What are the recurrence rates, complications, and functional outcomes after multiportal arthroscopic synovectomy for patients with knee diffuse-type tenosynovial giant-cell tumors?","volume":"482","author":"Yao","year":"2024","journal-title":"Clin Orthop Relat Res"},{"key":"R23-20250813","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5435\/00124635-200606000-00007","article-title":"Pigmented villonodular synovitis","volume":"14","author":"Tyler","year":"2006","journal-title":"J Am Acad Orthop Surg"},{"key":"R24-20250813","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00167-014-3375-9","article-title":"Combined arthroscopic and open synovectomy for diffuse pigmented villonodular synovitis of the knee","volume":"24","author":"Mollon","year":"2016","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"R25-20250813","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11999-012-2589-8","article-title":"Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates?","volume":"471","author":"Colman","year":"2013","journal-title":"Clin Orthop Relat Res"},{"key":"R26-20250813","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.arth.2016.12.053","article-title":"Prognosis of advanced tenosynovial giant cell tumor of the knee diagnosed during total knee arthroplasty","volume":"32","author":"Lei","year":"2017","journal-title":"J Arthroplasty"},{"key":"R27-20250813","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2106\/00004623-199801000-00013","article-title":"Total knee arthroplasty in patients who have pigmented villonodular synovitis","volume":"80","author":"Hamlin","year":"1998","journal-title":"J Bone Joint Surg Am"},{"key":"R28-20250813","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11420-012-9283-y","article-title":"MRI diagnosis of recurrent pigmented villonodular synovitis following total joint arthroplasty","volume":"9","author":"Friedman","year":"2013","journal-title":"HSS J"},{"key":"R29-20250813","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arth.2018.08.041","article-title":"Complications after total knee arthroplasty in patients with pigmented villonodular synovitis","volume":"34","author":"Casp","year":"2019","journal-title":"J Arthroplasty"},{"key":"R30-20250813","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12306-023-00793-y","article-title":"Total knee arthroplasty in pigmented villonodular synovitis osteoarthritis: A systematic review of literature","volume":"108","author":"Panciera","year":"2024","journal-title":"Musculoskelet Surg"},{"key":"R31-20250813","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2106\/00004623-199801000-00013","article-title":"Total knee arthroplasty in patients who have pigmented villonodular synovitis","volume":"80","author":"Hamlin","year":"1998","journal-title":"J Bone Joint Surg Am"},{"key":"R32-20250813","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.knee.2017.04.019","article-title":"Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis","volume":"24","author":"Houdek","year":"2017","journal-title":"Knee"},{"key":"R33-20250813","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/jso.27067","article-title":"A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis","volume":"126","author":"Bernthal","year":"2022","journal-title":"J Surg Oncol"},{"key":"R34-20250813","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1093\/oncolo\/oyad011","article-title":"Tenosynovial giant cell tumor observational platform project (TOPP) registry: A 2-year analysis of patient-reported outcomes and treatment strategies","volume":"28","author":"Palmerini","year":"2023","journal-title":"Oncologist"},{"key":"R35-20250813","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/rheumatology\/kel352","article-title":"Therapeutic status of radiosynoviorthesis of the knee with yttrium [90Y] colloid in rheumatoid arthritis and related indications","volume":"46","author":"Kampen","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R36-20250813","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/rheumatology\/41.10.1113","article-title":"The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints","volume":"41","author":"Shabat","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20250813","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40268-020-00314-3","article-title":"Pexidartinib (TURALIO\u2122): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor","volume":"20","author":"Monestime","year":"2020","journal-title":"Drugs R D"},{"key":"R38-20250813","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"key":"R39-20250813","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"R40-20250813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14796694.2024.2396227","article-title":"MANEUVER: A phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients","volume":"17","author":"Niu","year":"2024","journal-title":"Future Oncol"},{"key":"R41-20250813","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neulet.2014.09.053","article-title":"Intra-articular administration of an antibody against CSF-1 receptor reduces pain-related behaviors and inflammation in CFA-induced knee arthritis","volume":"584","author":"Alvarado-Vazquez","year":"2015","journal-title":"Neurosci Lett"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-01255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:39:34Z","timestamp":1787668774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-01255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-24-01255","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"2024-10-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}